Cell

Guidelines for Reporting Experiments on Cell Aging in Living Organisms

Updated

Abstract

Practical guidelines for identifying senescent cells in vivo are provided through the 'minimum information for cellular senescence experimentation in vivo' (MICSE).

  • Cellular senescence is associated with stable cell-cycle arrest and a hypersecretory state in response to stress.
  • Senescence has diverse roles in biological processes, including tissue repair and chronic disease.
  • New tools for studying senescence in living organisms may help uncover its physiological and pathological roles.
  • A lack of specific markers has hindered the identification and characterization of senescent cells in various tissues.
  • The MICSE guidelines offer an overview of senescence markers across different species and tissues to aid in research.

Simplified

Full Text

Full text is available at the source.

Funding

Competing interests

Declaration of interests D.J.B. has potential financial interests related to this study. He is a co-inventor of patents held by the Mayo Clinic, patent applications licensed to or filed by Unity Biotechnology, and a Unity Biotechnology shareholder. Research in the Baker laboratory has been reviewed by the Mayo Clinic Conflict of Interest Review Board and is being conducted in compliance with Mayo Clinic Conflict of Interest policies. J. Gil has acted as a consultant for Unity Biotechnology, Geras Bio, Myricx Pharma Ltd., and Merck KGaA; owns equity in Geras Bio and share options in Myricx Pharma Ltd.; and is a named inventor in MRC and Imperial College patents related to senolytic therapies. J. Gil currently receives funding from Pfizer. Unity Biotechnology funded research on senolytics in J. Gil’s laboratory in the past. SenTraGor and GLF16 senescence detection compounds are under patent applications: EP3475287B1, and 20240100309 (Greek patent application) along with GB2406749.8 (UK patent application), respectively. J.M.S. is a co-inventor on patents held by Brown University on methods to inhibit retrotransposon activation in age-related diseases. He is the scientific co-founder of Transposon Therapeutics, chair of their scientific advisory board, and a consultant and holds stock options. He is also a consultant and holds equity in Atropos Therapeutics. Research in the Sedivy laboratory has been reviewed by the Brown University Conflict of Interest Review Board and is being conducted in compliance with Brown University Conflict of Interest policies. F.d.d.F. is an inventor on the patent applications PCT/EP2013/059753 and PCT/EP2016/068162. M.D. is co-inventor on patents held by the Buck Institute for Research on Aging. He is the scientific co-founder of Cleara Biotech and consultant for Oisin Biotechnologies. M.D.’s laboratory currently receives research funding from Ono Pharmaceuticals. J. Grillari is co-inventor on patents held by BOKU and is a co-founder and scientific advisor to TAmiRNA and Rockfish Bio.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free